Trial intelligence / Profile preview

Macitentan in chronic thromboembolic pulmonary hypertension (CTEPH)

CTR20211317Phase 3Terminated

Sponsor
Actelion Pharmaceuticals Ltd
Start
Jun 2021
Modality
Small Molecules
Countries
1
01

Overview

A Phase 3 trial of macitentan in chronic thromboembolic pulmonary hypertension (CTEPH), sponsored by Actelion Pharmaceuticals Ltd. Started Jun 2021; status: terminated.

02

Drugs

macitentan
03

Conditions

chronic thromboembolic pulmonary hypertension (CTEPH)

Beyond the preview

Go deeper on CTR20211317.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20211317.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call